Dr. Panos Kosmas to Deliver Keynote Lecture on New Medical Technology for Stroke Detection
Meta Materials Inc. (NASDAQ:MMAT) announced a significant milestone with a new U.S. patent enhancing its position in medical imaging. Dr. Panos Kosmas will present at the 8th International Conference on Antennas and Electromagnetic Systems in Morocco on May 26, discussing a portable radio-wave imaging scanner aimed at improving stroke diagnosis. The technology, developed through collaboration with King's College London, promises accurate stroke detection, potentially reducing treatment response times. Meta's patented metamaterial technology supports advancements in medical diagnostics, addressing a global health issue impacting millions.
- New U.S. patent strengthens META's intellectual property in medical imaging.
- Development of a portable imaging scanner may lead to faster stroke diagnosis.
- Collaboration with King's College London enhances research credibility.
- Potential for broad applications in various medical imaging areas.
- None.
U.S. Patent Strengthens META's Intellectual Property Position in Medical Imaging
HALIFAX, NS / ACCESSWIRE / May 25, 2022 / Meta Materials Inc. (the "Company" or "META®") (NASDAQ:MMAT),(FSE:MMAT) a developer of high-performance functional materials and nanocomposites, today announced that Dr. Panos Kosmas, VP Biomedical Engineering, will give a keynote lecture on Microwave Imaging for Medical Diagnostics on Thursday, May 26th, as part of the 8th International Conference on Antennas and Electromagnetic Systems (AES 2022) held in Marrakesh, Morocco. As part of his lecture, Dr. Kosmas will provide an overview of his team's R&D towards developing a portable, cost effective and safe radio-wave imaging scanner, which can be used in ambulances for detecting strokes, or bedside in the hospital to monitor stroke evolution and recovery.
According to the World Stroke Organization, stroke remains the second-leading cause of death and the third-leading cause of death and disability combined in the world. The estimated global cost of stroke is over U.S.
Point of care diagnostics and remote monitoring crucially depend on data accuracy and reliability. META has developed a metamaterial technology platform to measure physiological signals with superior accuracy, specificity, and sensitivity. META's technology leverages metamaterials to bend light in non-ordinary ways. When a metamaterial film is placed on the skin, the signal can penetrate the tissue, improving sensing accuracy. Under normal circumstances, a signal is reflected, and little energy penetrates the tissue, hindering sensing accuracy.
"The application of metamaterials in medical imaging has the potential for rapid clinical adoption, providing higher image resolution, faster scans and without using ionizing radiation. Our technology leads to the development of improved diagnostic tools," said George Palikaras, President & CEO. "META has demonstrated and published the effectiveness of metamaterial technology in both imaging and sensing applications. I am personally excited about how this technology will make a difference in people's lives."
The research is the result of a collaboration between King's College London, where Dr. Kosmas previously held a full-time academic position, and META, where he is now employed full-time leading the effort to commercialize this research. Development of the portable scanner benefits from META's patented, "see-through-skin" metamaterial technology, which is a key enabler for detecting stroke more accurately. META's approach has been presented in a series of peer-reviewed papers and has recently been granted a U.S. patent (US 11,246,502 B2). The system is currently being developed further in META's new European R&D and Sales Headquarters in Athens, Greece.
"Timely differential diagnosis of stroke is critical, since the window for treatment to mitigate lasting damage is short," said Dr. Kosmas. "With our planned, portable system, medication to treat an ischemic stroke by dissolving blood clots could be administered while the patient is still on the ambulance, and in the case of a hemorrhagic stroke, preparation for surgical intervention could begin before the patient arrives at the hospital, saving critical time in a life and death situation, or what healthcare professionals call the golden hour."
The radio wave tomography system described in META's U.S. patent covers a broad range of potential applications, including breast imaging for cancer, brain imaging for clots, bleeding and other abnormalities, and post trauma diagnosis of internal bleeding and/or broken bones. Radio wave tomography depends on optimized evaluation algorithms, big data, and powerful computers. The technique was not adequately developed until recently, as the cost of hardware has declined, and sufficient computing power has become available.
About Meta Materials Inc.
META® delivers previously unachievable performance, across a range of applications, by inventing, designing, developing, and manufacturing sustainable, highly functional materials. Our extensive technology platform enables leading global brands to deliver breakthrough products to their customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. Our nano-optic technology provides anti-counterfeiting security features for government documents and currencies and authentication for brands. Our achievements have been widely recognized, including being named a Lux Research Innovator of the Year in 2021. Learn more at www.metamaterial.com.
Forward Looking Information
This press release includes forward-looking information or statements within the meaning of Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, regarding the Company, which may include, but are not limited to, statements with respect to the business strategies, product development, expansion plans and operational activities of the Company . Often but not always, forward-looking information can be identified by the use of words such as "pursuing", "potential", "predicts", "projects", "seeks", "plans", "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "should", "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, the capabilities of our facilities and the expansion thereof, research and development projects of the Company, the market potential of the products of the Company , the market position of the Company, the scalability of the Company's production ability, capacity for new customer engagements, material selection programs timeframes, the ability to reduce production costs, enhance metamaterials manufacturing capabilities and extend market reach into new applications and industries, the ability to accelerate commercialization plans, the possibility of new customer contracts, the continued engagement of our employees, the technology industry, market strategic and operational activities, and management's ability to manage and to operate the business. More details about these and other risks that may impact the Company's businesses are described under the heading "Forward-Looking Information" and under the heading "Risk Factors" in the Company's Form 10-K filed with the SEC on March 1, 2022, with an SEC filing date of March 2, in the Company's Form 10-Q filed with the SEC on May 10, 2022, and in subsequent filings made by Meta Materials with the SEC, which are available on SEC's website at www.sec.gov. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required by law.
Media Inquiries
Rob Stone
Vice President, Corporate Development and Communications
Meta Materials Inc.
media@metamaterial.com
Investor Contact
Mark Komonoski
Senior Vice President
Integrous Communications
Phone: 1-877-255-8483
Email: ir@metamaterial.com
SOURCE: Meta Materials Inc.
View source version on accesswire.com:
https://www.accesswire.com/702606/Dr-Panos-Kosmas-to-Deliver-Keynote-Lecture-on-New-Medical-Technology-for-Stroke-Detection
FAQ
What is the significance of the new U.S. patent for Meta Materials (MMAT)?
What technology is Meta developing for stroke detection?
When is Dr. Panos Kosmas presenting at the International Conference?
How does Meta's technology improve medical diagnostics?
What are the potential applications of Meta's radio wave tomography system?
